Cargando…
The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
Inhibition of BRAF improves therapeutic efficacy of BRAF-mutant melanoma. However, drug resistance to BRAF inhibitor is inevitable, and the drug resistance mechanisms still remain to be elucidated. Here, BRAF(V600E) mutant cells A375 and SK-MEL-28 were chosen and treated with BRAF inhibitor vemurafe...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221393/ https://www.ncbi.nlm.nih.gov/pubmed/30192303 http://dx.doi.org/10.1097/CMR.0000000000000497 |